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Oestrogen receptor status is useful for assessing the
likelihood of response to endocrine therapy in advanced
breast cancer (Jensen et al., 1971; McGuire et al., 1975;
Roberts et al., 1978) and may also serve as a prognostic
index in early disease (Clark & McGuire, 1983; Knight et al.,
1977; Nicholson et al., 1981). In general terms, about 55%
of receptor-positive tumours will respond to endocrine
therapy whereas only 5% of receptor-negative tumours will
do so (Hawkins et al., 1980). It is well established that
oestrogen receptor level is a function of tumour cellularity
(Masters et al., 1978; Hawkins et al., 1981) and for accurate
identification of receptor-negative tumours, it is clearly
important to be certain that the material being assayed
contains an adequate amount of neoplastic tissue. In this
department it has been a strict policy to set aside for
microscopic assessment a portion of the actual tissue being
assayed, in addition to sending 'adjacent' tissue for formal
histological examination by the Department of Pathology. A
study has therefore been carried out to establish whether this
control histology is of value in detecting false-negative results
for the receptor assay.
All tissues from breast cancer patients (512) submitted for
oestrogen receptor estimation during 1983 were studied.
Apart from clinically involved lymph nodes from patients
with histologically proven breast cancer, all fresh specimens
removed by the surgeon had been sent immediately to a
pathologist who divided the suspected tumour tissue into
two portions - one for formal histology and one for
laboratory purposes including oestrogen receptor assay. In
each case, a section was then cut with a skin-graft blade
from the face of the actual tissue used for receptor
estimation, and stained using haematoxylin and eosin.
Oestrogen receptor estimation was carried out by
saturation analysis of homogenised tumour with separation
of free and bound hormone by dextran-coated charcoal
adsorption (Hawkins et al., 1975,1981). The dissociation
constant of binding and the receptor concentration were
calculated by Scatchard analysis (Scatchard, 1949) and the
receptor level was expressed as fmol binding sitesmg- 1
cytosol protein, protein being estimated by the method of
Bradford (1976). Tissues containing <5fmolmg-t protein
were regarded as receptor-negative, as values below this
approach the error of the method.
For all tissues which were receptor-negative, the control
histology was reviewed by one of us (RJCS). If adequate
tumour was noted by the pathologist in the formal histology
report, but tumour constituted none or < 10% of the control
section, regardless of cellularity, the tissue assayed for
oestrogen receptors was classified as unsatisfactory for the
purpose of biochemical assay. When the percentage of
tumour on any section was in doubt, the slide was projected
on to a screen and a fine grid was superimposed, using an
overhead projector. The percentage of the section made up
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by tumour could then be estimated by counting the number
of squares overlying the malignant and benign tissue areas.
Overall, 512 tissues from breast cancer patients were sent
for oestrogen receptor estimation. These comprised 472
assumed primary tumours, 10 assumed secondary deposits,
and 30 clinically involved lymph nodes. In all cases, the
patients from whom these tissues were removed had breast
cancer proven on formal histology. In 15 instances, receptor
assay was not performed. This was because at reception,
macroscopically the tissue appeared unlikely to contain
tumour and assay had been delayed until the result of formal
and control histology examinations were available; for these
15 tissues it was shown that no tumour was present and
assay was therefore unwarranted. Of the remaining 497
tissues, 131 (26%) were oestrogen receptor-negative, and, of
these, 32 (24%) were regarded as histologically
unsatisfactory; when the latter were excluded, the oestrogen
receptor-negative rate was reduced from 26% (131/497) to
21% (99/465). The breakdown of oestrogen receptor-negative
tissues is given in Table I: 22% of 'primary tumours' and
50% of 'metastases' in lymph nodes were histologically
unsatisfactory.
This study demonstrates that histological confirmation of
suspected tumour tissue must be carried out on a section
from the actual specimen which is to be used for receptor
estimation if false negative results are to be avoided. It is not
sufficient to rely on microscopic examination of a separate,
albeit adjacent, piece of tissue, as macroscopic appearances
can be misleading. This is particularly true of the clinically
involved lymph node, even when it has been excised and
bisected by an experienced surgeon.
No criticism is levelled at the pathologists, as it is their
duty to obtain an adequate sample of any tumour in order
to allow thorough histological scrutiny. However, the
biochemist who is to perform receptor assays may, of
necessity, be left with a small portion of tissue, especially if
other research interests are involved. We therefore believe
that it is mandatory that he carries out his own histological
checks, preferably aided by an experienced pathologist.
Despite the value of this second or control histological check
in assessing the adequacy/otherwise of the specimen used for
biochemical assays of receptor activity, this procedure still
suffers from some deficiencies. It must be noted that no
Table I The incidence of 'false negatives' in 131 breast cancers
deemed to be oestrogen receptor negative by assay.
Primary tumour Node Metastatic deposit




Total 116 12 3
aHistology was designated as 'unsatisfactory' when tumour
constituted < 10% of the tissue specimen used for receptor analysis.
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additional examination of the control histology was carried
out for the receptor-positives. Furthermore, in view of the
heterogeneity of breast tumours, removal and assessment of
the control section from one face of the receptor specimen,
whilst it represents an improvement over no histological
check, does not necessarily reflect accurately the tumour
content of the entire specimen. There is no completely
satisfactory solution to this problem, though Van Netten et
al. (1986) using a microsample technique, and Underwood et
al. (1986), using 40,um frozen sections, have reported
methods for more accurately analysing receptor content in
relation to morphology.
It is now possible to detect the oestrogen receptor using
both immunohistochemical techniques (ERICA) on frozen
sections of tissue (King et al., 1983; Hawkins et al., 1986),
and immunoassays (EIA) on fine needle aspirates of tumour
(Magdelenat, 1986). These methods do not rely on
radioligand binding and should be applicable to smaller
samples of tissue for which the relevant histological check
will be readily available, obviating the problems of false
negatives due to inadequate specimens. However, immuno-
histochemistry may prove difficult to quantify accurately and
the enzymimmunoassay on fine needle aspirates is not yet
widely established. It seems likely, therefore, that for some
time to come, biochemical assays (radioligand-binding or
EIA) will still be performed on excised solid tumour
specimens; for these a careful histological check will remain
important.
In conclusion, 'control histology', although only a crude
guide to the tumour content of the actual specimen used for
assay, is, for the present, a vital step in eliminating false
negative results for oestrogen receptor assays.
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